Best response to lenalidomide-bortezomib-dexamethasone
| . | N = 64 . | ||
|---|---|---|---|
| Response . | n . | % . | 90% CI . |
| CR | 7 | 11 | 5-20 |
| nCR | 9 | 14 | 8-23 |
| VGPR | 2 | 3 | 1-10 |
| PR | 23 | 36 | 26-47 |
| MR | 10 | 16 | 9-25 |
| SD | 10 | 16 | 9-25 |
| PD | 1 | 2 | 0.1-7 |
| Not evaluable* | 2 | 3 | 1-10 |
| CR+nCR | 16 | 25 | 16-36 |
| CR+nCR+VGPR | 18 | 28 | 19-39 |
| At least PR | 41 | 64 | 53-74 |
| At least MR | 51 | 80 | 70-88 |
| . | N = 64 . | ||
|---|---|---|---|
| Response . | n . | % . | 90% CI . |
| CR | 7 | 11 | 5-20 |
| nCR | 9 | 14 | 8-23 |
| VGPR | 2 | 3 | 1-10 |
| PR | 23 | 36 | 26-47 |
| MR | 10 | 16 | 9-25 |
| SD | 10 | 16 | 9-25 |
| PD | 1 | 2 | 0.1-7 |
| Not evaluable* | 2 | 3 | 1-10 |
| CR+nCR | 16 | 25 | 16-36 |
| CR+nCR+VGPR | 18 | 28 | 19-39 |
| At least PR | 41 | 64 | 53-74 |
| At least MR | 51 | 80 | 70-88 |
Two patients were not evaluable for response; 1 received <1 cycle and 1 had nonmeasurable disease.